Jove
Visualize
お問い合わせ

関連する概念動画

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.2K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

944
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
944
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

401
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
401
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

345
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
345
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

232
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
232
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

352
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
352
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー
  1. ホーム
  3. 冠動脈および外周動脈疾患の患者における抗血小板剤と経口抗凝固剤の組み合わせ
  1. ホーム
  3. 冠動脈および外周動脈疾患の患者における抗血小板剤と経口抗凝固剤の組み合わせ

関連する実験動画

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

1.9K

冠動脈および外周動脈疾患の患者における抗血小板剤と経口抗凝固剤の組み合わせ

Paul A Gurbel1, Keith A A Fox2, Udaya S Tantry3

  • 1Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Falls Church, VA (P.A.G.).

Circulation
|April 30, 2019

PubMed で要約を見る

まとめ
この要約は機械生成です。

二重抗血小板治療は動脈疾患の標準ですが,急性冠動脈症候群および外周動脈疾患の患者でよりよい結果を得るために,抗凝固剤と併用することが検討されています.

キーワード:
抗凝固剤アスピリン血液の凝固血小板冠動脈疾患ファクターXA阻害剤外周動脈疾患リバロキサバン

さらに関連する動画

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

821
Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA
13:10

Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA

Published on: April 24, 2017

19.2K

関連する実験動画

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
13:48

Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound

Published on: April 21, 2023

1.9K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

821
Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA
13:10

Direct Re-implantation of Left Coronary Artery into the Aorta in Adults with Anomalous Origin of Left Coronary Artery from the Pulmonary Artery ALCAPA

Published on: April 24, 2017

19.2K

科学分野:

  • 心血管医学
  • 血液学
  • 薬理学について

背景:

  • アスピリンとクロピドグレルまたはより強力なP2Y12阻害剤による二重抗血小板療法 (DAPT) を含む抗血小板治療は,冠動脈および外周動脈疾患の管理の標準です.
  • DAPTにもかかわらず,急性冠動脈症候群 (ACS) の1年以内に約10%の患者が再発性血栓症を起こします.

研究 の 目的:

  • 動脈血栓症における血小板と凝固因子の役割に関する理解の進化をレビューする.
  • 冠動脈および外周動脈疾患の患者における抗血小板剤と経口抗凝固剤の併用に関する論理的根拠と臨床的証拠について議論する.

主な方法:

  • 動脈血栓症,抗血小板療法,抗凝固療法に関する現在の文献のレビュー.
  • 抗血小板剤と抗凝固剤の組み合わせを調査した臨床試験データの分析
  • 凝固因子の阻害に関する基礎的および翻訳的研究の探索.

主要な成果:

  • DAPTは単体治療と比較して成果を上げているが,再発防止には限界がある.
  • P2Y12阻害剤を投与された患者では,アスピリンと共にまたは代わりに,低用量の経口抗凝固剤を投与する.
  • 新興の研究は,凝固因子抑制の非正規的な効果が臨床的効果を高める可能性があることを示唆している.

結論:

  • 強力な抗血小板療法にもかかわらず,再発性血栓症は依然として課題です.
  • 抗血小板薬と経口抗凝固薬の併用は,動脈血栓性疾患の治療結果を改善するための研究分野です.
  • 安全性と有効性を最適化するためにさらなる研究が必要である.